BR112015004165A2 - métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas - Google Patents

métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas

Info

Publication number
BR112015004165A2
BR112015004165A2 BR112015004165A BR112015004165A BR112015004165A2 BR 112015004165 A2 BR112015004165 A2 BR 112015004165A2 BR 112015004165 A BR112015004165 A BR 112015004165A BR 112015004165 A BR112015004165 A BR 112015004165A BR 112015004165 A2 BR112015004165 A2 BR 112015004165A2
Authority
BR
Brazil
Prior art keywords
constipation
compositions
treatment
alternative embodiments
provides
Prior art date
Application number
BR112015004165A
Other languages
English (en)
Inventor
Julius Borody Thomas
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of BR112015004165A2 publication Critical patent/BR112015004165A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas". a presente invenção refere-se as modalidades alternativas, a invenção fornece as composições, por exemplo, as formulações ou as preparações, empregadas para o tratamento, a melhora ou a prevenção da constipação e outros distúrbios com os sintomas gastrointestinais relacionados. nas modalidades alternativas, a invenção fornece as composições, por exemplo, as formulações ou as preparações, empregadas para o tratamento, a melhora ou a prevenção das condições que se beneficiam do aumento ou do aceleramento do trânsito do intestino, incluindo, por exemplo: vômitos cíclicos, esofagite de refluxo, autismo com enteropatia, flatulência, halitose, síndrome da fadiga crônica (cfs), inchaço, proctalgia fugaz, super crescimento bacteriano no intestino delgado (sibo) e super crescimento bacteriano no intestino delgado (libo), nâusea crônica, dispepsia funcional e inchaço. nas modalidades alternativas, a invenção fornece as composições, por exemplo, as formulações ou as preparações, empregadas para o tratamento, a melhora ou a prevenção de uma constipação, uma constipação funcional, constipação de síndrome do intestino irritável (ibs), uma constipação associada a diverticulose, uma pseudo obstrução, uma constipação de trânsito lento, uma estase com fluxo constante e/ou uma gastro-paresia diabética. nas modalidades alternativas, a invenção fornece produtos (artigos) e farmacêuticos de produção para a liberação destas composições e formulações a um indivíduo, por exemplo, um humano ou um animal.
BR112015004165A 2012-08-29 2013-08-29 métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas BR112015004165A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261694672P 2012-08-29 2012-08-29
US201261723027P 2012-11-06 2012-11-06
PCT/AU2013/000973 WO2014032108A1 (en) 2012-08-29 2013-08-29 Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions

Publications (1)

Publication Number Publication Date
BR112015004165A2 true BR112015004165A2 (pt) 2017-07-04

Family

ID=50182266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004165A BR112015004165A2 (pt) 2012-08-29 2013-08-29 métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas

Country Status (15)

Country Link
US (1) US20150216806A1 (pt)
EP (1) EP2890367A4 (pt)
JP (1) JP2015531770A (pt)
KR (1) KR20150046310A (pt)
CN (1) CN104936581A (pt)
AU (1) AU2013308403B2 (pt)
BR (1) BR112015004165A2 (pt)
CA (1) CA2882316A1 (pt)
HK (1) HK1212222A1 (pt)
IL (1) IL237276A0 (pt)
IN (1) IN2015DN01857A (pt)
MX (1) MX2015002210A (pt)
PH (1) PH12015500435A1 (pt)
RU (1) RU2015111258A (pt)
WO (1) WO2014032108A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
PT2968174T (pt) 2013-03-15 2020-01-15 Braintree Laboratories Inc Comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e seus métodos de utilização
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2014176632A1 (en) * 2013-04-30 2014-11-06 Borody Thomas J Compositions and methods for treating microbiota-related psychotropic conditions and diseases
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
EP3079661B1 (de) 2013-12-11 2021-05-05 Algobate AG Naloxon-monopräparat und mehrschichttablette
US10105360B2 (en) * 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
RO130546B1 (ro) * 2014-04-28 2019-03-29 Mariana Lisinschi Unguent pentru tratamentul bolii hemoroidale
CA2947434A1 (en) 2014-04-29 2015-11-05 Colonaryconcepts Llc Foods, systems, methods, and kits for providing electrolyte replacement
ME02997B (me) 2014-12-23 2018-10-20 4D Pharma Res Ltd Soj bacteroides thetaiotaomicron i njegova upotreba u smanjenju inflamacije
WO2016102951A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
WO2016140981A1 (en) 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN107750124B (zh) * 2015-05-06 2022-10-28 波利维逊有限公司 用于降低微生物污染的抗微生物组合物和方法
PL3206700T3 (pl) 2015-06-15 2019-11-29 4D Pharma Res Ltd Kompozycje zawierające szczepy bakteryjne
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN115364122A (zh) 2015-06-15 2022-11-22 4D制药研究有限公司 包含细菌菌株的组合物
MD3307288T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
JP2018523694A (ja) 2015-08-17 2018-08-23 フェリング ベスローテン フェンノートシャップ ピコスルファートおよびクエン酸マグネシウムを含む液体製剤
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EA034677B1 (ru) 2015-11-20 2020-03-05 4Д Фарма Рисёрч Лимитед Композиции для лечения или профилактики рака, содержащие штамм enterococcus gallinarum
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR101811032B1 (ko) * 2016-01-28 2017-12-20 주식회사 씨티씨바이오 하제 조성물
DK3313423T3 (da) 2016-03-04 2019-05-20 4D Pharma Plc Sammensætninger omfattende bakterielle blautia-stammer til behandling af visceral hypersensitivitet
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CA3018589A1 (en) * 2016-03-29 2017-10-05 Colonaryconcepts Llc Formulations for treating constipation
WO2017218894A1 (en) 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CN106556666A (zh) * 2016-11-02 2017-04-05 陕西嘉禾生物科技股份有限公司 一种欧鼠李皮和美鼠李皮的薄层鉴定方法
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN106830417B (zh) * 2017-01-12 2021-05-11 新宇药业股份有限公司 一种高效降解废水中林可霉素的处理方法
CN107616983A (zh) * 2017-01-13 2018-01-23 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
CN107616984A (zh) * 2017-01-13 2018-01-23 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
CN107518411A (zh) * 2017-01-13 2017-12-29 江苏西宏生物医药有限公司 一种抗腹泻的经肠营养组合物
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
LT3630136T (lt) 2017-05-22 2021-06-10 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Preparations containing bacterial strains
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
WO2019140316A1 (en) * 2018-01-12 2019-07-18 Colonaryconcepts Llc Solid concentrated constipation treatment formulations
US20200383934A1 (en) * 2018-01-12 2020-12-10 Colonaryconcepts Llc Constipation specific treatment formulations
US11224590B2 (en) * 2018-03-16 2022-01-18 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
CN115581699A (zh) * 2018-04-28 2023-01-10 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物及其制备方法
CN110403945B (zh) * 2018-04-28 2022-11-18 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物及其制备方法
CN108819052A (zh) * 2018-05-04 2018-11-16 苏州捷德瑞精密机械有限公司 一种树脂基体系用脱模剂及其制备方法
CN112400024B (zh) * 2018-06-01 2024-04-09 比奥拉治疗股份有限公司 用于胃肠道微生物组检测和处理的装置和系统
JP6661712B2 (ja) * 2018-08-15 2020-03-11 旭化成ワッカーシリコーン株式会社 シリコーン消泡剤組成物、および、シリコーン消泡剤組成物の製造方法。
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物
CN109337098B (zh) * 2018-11-23 2021-02-02 哈尔滨工程大学 一种酶响应型结肠靶向载药凝胶的制备方法
CN109749960B (zh) * 2019-01-31 2020-05-26 上海宝藤生物医药科技股份有限公司 基于多种肠道细菌含量评估便秘风险及便秘程度的方法及装置
US10857092B2 (en) * 2019-03-14 2020-12-08 Glen D Lindbo Avoiding gag reflex to enable swallowing pills
JP2022526495A (ja) * 2019-03-18 2022-05-25 シーダーズ－サイナイ・メディカル・センター 胃腸疾患および障害を治療するための組成物およびその方法
CN110051655A (zh) * 2019-03-19 2019-07-26 吉林省盛赛医药实业有限公司 一种治疗便秘的复方制剂的制备方法
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
TW202116342A (zh) * 2019-07-08 2021-05-01 薩摩亞商吉亞生技控股股份有限公司 改善或抑制胃腸道不適的組合物及方法
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) * 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
CN112386577B (zh) * 2019-08-16 2024-01-23 北京天衡药物研究院有限公司 一种治疗便秘的组合物
RU2716144C1 (ru) * 2019-09-23 2020-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ консервативного лечения послеоперационного пареза кишечника у новорожденных детей
CN110833537B (zh) * 2019-11-15 2021-04-13 三峡大学 药物缓释材料及其在制备治疗直肠炎的缓释材料上的应用
RU2740488C1 (ru) * 2020-06-05 2021-01-14 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт травматологии и ортопедии им. Я.Л. Цивьяна" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТО им. Я.Л. Цивьяна" Минздрава России) Способ объективной диагностики/прогнозирования пареза желудочно-кишечного тракта
CN111920798A (zh) * 2020-06-24 2020-11-13 首都医科大学附属北京同仁医院 一种硝呋酚酰肼在制备药物中的应用
CN112843077A (zh) * 2020-09-08 2021-05-28 天津国际生物医药联合研究院 表柔比星或者硫酸博来霉素在抗分枝杆菌感染中的潜在应用
CN112189761A (zh) * 2020-10-30 2021-01-08 安佑生物科技集团股份有限公司 一种防治动物便秘的饲料添加剂及其制备方法和应用
CN114869879B (zh) * 2022-05-09 2024-06-25 南方医科大学珠江医院 一种具备活性氧和炎症双重抑制作用的小分子水凝胶及其制备方法
CN114965764A (zh) * 2022-05-18 2022-08-30 陕西安宁云生生物技术有限公司 便秘的诊断和治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA761927A (en) * 1967-06-27 Seeger Ernst Benzoxazine derivatives
AU757343B2 (en) * 1998-09-28 2003-02-20 Capsugel Belgium Nv Enteric and colonic delivery using HPMC capsules
CN1288730A (zh) * 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
DK1225897T3 (da) * 1999-11-01 2005-01-10 John Rhodes Sammensætning til behandling af obstipation og colon irritabile
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
WO2004062577A2 (en) * 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
BR112013014827A2 (pt) * 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas

Also Published As

Publication number Publication date
EP2890367A4 (en) 2016-03-30
MX2015002210A (es) 2015-05-08
KR20150046310A (ko) 2015-04-29
IL237276A0 (en) 2015-04-30
CA2882316A1 (en) 2014-03-06
HK1212222A1 (en) 2016-06-10
EP2890367A1 (en) 2015-07-08
US20150216806A1 (en) 2015-08-06
IN2015DN01857A (pt) 2015-05-29
CN104936581A (zh) 2015-09-23
JP2015531770A (ja) 2015-11-05
PH12015500435A1 (en) 2015-04-20
RU2015111258A (ru) 2016-10-20
WO2014032108A1 (en) 2014-03-06
AU2013308403B2 (en) 2019-02-07
AU2013308403A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
BR112015004165A2 (pt) métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112017011078A2 (pt) composições de kiwi ouro e métodos de preparação e uso das mesmas
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112013020312A2 (pt) composições simbióticas para restauração e reconstituição da microbiota intestinal
BR112012001297A2 (pt) conector.
BR112018017228A2 (pt) composições e métodos para regeneração do músculo usando prostaglandina e2
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BRPI0819323B8 (pt) composição à base de bactéria probiótica em associação com uma prebiótica e uso da mesma na prevenção e/ou tratamento de patologias respiratórias e/ou infecções e no aperfeiçoamento de funcionalidade intestinal
BR112017002627A2 (pt) prebióticos para reduzir o risco de obesidade no futuro
BR112013031485A2 (pt) &#34;anticorpos anti-psl de pseudomonas, seus método de produção e uso na prevenção ou no tratamento de infecção por pseudomonas, polinucleotídeo, 5 vetor, composição farmacêutica, bem como métodos in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais e para aumento de morte opsonofagocítica de p. aeruginosa&#34;
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
BR112013026661A2 (pt) método de entrega de vacina
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements